Navigation Links
Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets

PITTSBURGH, May 14 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has launched Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GlaxoSmithKline's (GSK) Paxil CR(R). As the first company to successfully file an abbreviated new drug application (ANDA) containing a paragraph IV certification for the 12.5 mg and 25 mg tablets, Mylan has earned 180 days of marketing exclusivity for these two strengths. Reflecting a supply and distribution agreement with GSK, Mylan also has the right to market the 37.5 mg strength. Mylan is not aware of any other ANDA filers with paragraph IV certifications for this product.

"As another first-to-file opportunity, Paroxetine HCl ER reflects Mylan's continued dynamic speed-to-market capabilities," says Robert J. Coury, Mylan's vice chairman and CEO. "Because this product also belongs in the 'difficult- to-manufacture' category, it is yet another example of our historically strong R&D process, through which we're able to deliver affordable versions of important complex therapies. Our settlement with GSK is consistent with our commitment to monetize opportunities when it benefits both patients and our shareholders."

Paroxetine HCl ER Tablets had U.S. sales of approximately $301 million for the 12 months ending March 31, 2008, for all three strengths.

In October 2007, Mylan announced the settlement of patent litigation involving Paroxetine HCl ER. At that time, Mylan stated that the settlement would provide the company with patent licenses and the right to market all three strengths beginning no later than Oct. 1, 2008. As part of the settlement agreement, which remains confidential, Mylan has been provided with the patent licenses needed to distribute the product immediately.

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
4. Mylan Announces Final FDA Approval for Trandolapril Tablets
5. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
6. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
7. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
8. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
9. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
10. Mylan Restores Availability of Generic Levothyroxine in Florida
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will experience death ... or animal pass away, death lives among us. It is your perspective, however, that ... family of 11 children, author T Sky understands that she may see death more ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that ... Their Ecosystem empowers dentists to make complex business decisions by providing the tools and ... a free fee survey with 10 procedures customized by zip code. , The ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in ... TIGR® Matrix is a long-term resorbable surgical mesh intended to support and reinforce ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability ... to the medical schools of the future. To reach an audience of key ... 2015 ChangeMedEd conference in Chicago, organized by the American Medical Association. , ...
(Date:11/30/2015)... CALIF. (PRWEB) , ... November ... ... ( ), a leading provider of enterprise Time and Attendance/Workforce Management ... status in the Microsoft Partner Program with competencies in the Application Development, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Belgium , Nov. 30, 2015 ... sciences company focused on developing blood-based diagnostic tests for a ... the Company will present at the LD Micro Conference, which ... Los Angeles, CA. Attending from VolitionRx will be ... Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
(Date:11/30/2015)... 2015 Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ... Kentucky Breast Care to increase collaboration with sub-specialists around ... patients. --> Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ...
Breaking Medicine Technology: